Abstract
Alzheimer’s disease is one of the most common causes of dementia and death in elderly populations. However, therapeutic intervention in Alzheimer’s disease is limited by the blood-brain barrier, which not only protects the brain by limiting the permeation of potential toxins into neural tissue but also by blocking certain drugs aimed at neurological disorders. MKT-077 is one such drug, which has shown promise in reducing Alzheimer’s disease- related pathology in cellular models but has limited brain permeation due to blockage by the blood-brain barrier. Herein, we describe the formulation and characterization of brain-targeted PEG-PLGA nanoparticles coated in 2% w/v glutathione to get higher blood-brain barrier permeation. Average nanoparticle size was found to be 230nm, suitable for intravenous administration and brain permeation. The nanoparticles showed steady, sustained release of MKT-077 in in vitro settings. Transwell in vitro blood-brain barrier model permeation studies showed the permeation of nanoparticles across the Transwell model to be greater than drug solution over 48 hours. The proposed model shows promise as a potential therapy against Alzheimer’s disease and other tauopathies.
Keywords: Alzheimer’s disease, blood-brain barrier, glutathione, MKT-077, nanoparticle, tau protein.
Pharmaceutical Nanotechnology
Title:Preparation and Characterization of MKT-077 Nanoparticles for Treatment of Alzheimer’s Disease and Other Tauopathies
Volume: 2 Issue: 4
Author(s): Umesh K. Jinwal, Aditya Grover, Malathi Narayan, Anjali Hirani and Vijaykumar Sutariya
Affiliation:
Keywords: Alzheimer’s disease, blood-brain barrier, glutathione, MKT-077, nanoparticle, tau protein.
Abstract: Alzheimer’s disease is one of the most common causes of dementia and death in elderly populations. However, therapeutic intervention in Alzheimer’s disease is limited by the blood-brain barrier, which not only protects the brain by limiting the permeation of potential toxins into neural tissue but also by blocking certain drugs aimed at neurological disorders. MKT-077 is one such drug, which has shown promise in reducing Alzheimer’s disease- related pathology in cellular models but has limited brain permeation due to blockage by the blood-brain barrier. Herein, we describe the formulation and characterization of brain-targeted PEG-PLGA nanoparticles coated in 2% w/v glutathione to get higher blood-brain barrier permeation. Average nanoparticle size was found to be 230nm, suitable for intravenous administration and brain permeation. The nanoparticles showed steady, sustained release of MKT-077 in in vitro settings. Transwell in vitro blood-brain barrier model permeation studies showed the permeation of nanoparticles across the Transwell model to be greater than drug solution over 48 hours. The proposed model shows promise as a potential therapy against Alzheimer’s disease and other tauopathies.
Export Options
About this article
Cite this article as:
K. Jinwal Umesh, Grover Aditya, Narayan Malathi, Hirani Anjali and Sutariya Vijaykumar, Preparation and Characterization of MKT-077 Nanoparticles for Treatment of Alzheimer’s Disease and Other Tauopathies, Pharmaceutical Nanotechnology 2014; 2 (4) . https://dx.doi.org/10.2174/2211738503666150328001726
DOI https://dx.doi.org/10.2174/2211738503666150328001726 |
Print ISSN 2211-7385 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-7393 |
Call for Papers in Thematic Issues
Polymeric nanocarriers in drug delivery
Polymeric nanocarriers play a crucial role in drug delivery due to their versatility, and unique properties for targeting and modifying drug release. Their ability to enhance therapeutic outcomes, reduce side effects, and enable the delivery of drugs in a more targeted and controlled manner made them popular in the last ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
NPY and Receptors in Immune and Inflammatory Diseases
Current Topics in Medicinal Chemistry Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia
Current Neurovascular Research Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in Experimental Myocarditis
Current Pharmaceutical Design The Biochemical Parameters and Vitamin D Levels in ICU Patients with Covid-19: A Cross-Sectional Study
Endocrine, Metabolic & Immune Disorders - Drug Targets The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry The Role of Oligodendrocytes in the Molecular Pathobiology and Potential Molecular Treatment of Cervical Spondylotic Myelopathy
Current Medicinal Chemistry Respiratory Tolerance in the Protection Against Asthma
Current Drug Targets - Inflammation & Allergy Pharmacological Perspectives of Wasp Venom
Protein & Peptide Letters Matrine: Bioactivities and Structural Modifications
Current Topics in Medicinal Chemistry Ion Channels on Microglia: Therapeutic Targets for Neuroprotection
CNS & Neurological Disorders - Drug Targets Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options
Current Neuropharmacology Brain Targeted Drug Delivery: Factors, Approaches and Patents
Recent Patents on Nanomedicine QSAR Study on a Series of Aryl Carboxylic Acid Amide Derivatives as Potential Inhibitors of Dihydroorotate Dehydrogenase (DHODH)
Medicinal Chemistry SIRT1 Promotes Neuronal Fortification in Neurodegenerative Diseases through Attenuation of Pathological Hallmarks and Enhancement of Cellular Lifespan
Current Neuropharmacology Neurotrophins - From Pathophysiology to Treatment in Alzheimers Disease
Current Alzheimer Research Mesenchymal Stem Cells Neuronal Differentiation Ability: A Real Perspective for Nervous System Repair?
Current Stem Cell Research & Therapy Round and Round we Go: Cyclic Peptides in Disease
Current Medicinal Chemistry NKT Cell Subsets Can Exert Opposing Effects in Autoimmunity, Tumor Surveillance and Inflammation
Current Immunology Reviews (Discontinued) Neuroprotective Properties of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) and its Lipid Ligands
Current Medicinal Chemistry Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Current Molecular Medicine